Wildcat Capital Management’s ImmunityBio IBRX Stock Holding History

Wildcat Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-492,000	Closed	-$600K	–	33
2019 Q3	$600K	Sell	492,000 -64,453	-12%	-$80K	0.25%	23
2019 Q2	$568K	Hold	556,453	–	–	0.25%	25
2019 Q1	$879K	Hold	556,453	–	–	0.52%	16
2018 Q4	$645K	Hold	556,453	–	–	0.42%	16
2018 Q3	$2.06M	Hold	556,453	–	–	1.59%	10
2018 Q2	$1.7M	Hold	556,453	–	–	1.3%	11
2018 Q1	$2.17M	Sell	556,453 -252,521	-31%	-$1.11M	1.79%	11
2017 Q4	$3.63M	Sell	808,974 -2,582,565	-76%	-$12.2M	3.86%	6
2017 Q3	$18.6M	Hold	3,391,539	–	–	3.33%	3
2017 Q2	$25.7M	Sell	3,391,539 -1,093,956	-24%	-$4.73M	6.84%	3
2017 Q1	$15.9M	Hold	4,485,495	–	–	5.04%	4
2016 Q4	$25.7M	Hold	4,485,495	–	–	11.8%	3
2016 Q3	$34.9M	Sell	4,485,495 -10,000	-0.2%	-$74.7K	10.52%	3
2016 Q2	$28M	Hold	4,495,495	–	–	10.54%	3
2016 Q1	$37M	Hold	4,495,495	–	–	12.85%	3
2015 Q4	$77.9M	Hold	4,495,495	–	–	21.98%	2
2015 Q3	$51.5M	Buy	+4,495,495	New	+$98.1M	19.23%	2

Other funds holding IBRX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Wildcat Capital Management's IBRX Position: Q4 2019 in Review

Wildcat Capital Management sold out of ImmunityBio (IBRX) in Q4 2019, closing a stake of 492,000 shares — an estimated $600K sold.

Wildcat Capital Management first reported a position in IBRX in Q3 2015 and held it in 17 quarters. The position peaked at $77.9M in Q4 2015. 47 funds tracked by Wall St. Rank hold IBRX as of Q4 2019.

Wildcat Capital Management reported no remaining ImmunityBio position as of Q4 2019 after selling out during the quarter.
Wildcat Capital Management sold 492,000 ImmunityBio shares in Q4 2019, an estimated $600K.
Wildcat Capital Management first reported a position in ImmunityBio in Q3 2015 and held it in 17 quarters.
Wildcat Capital Management's ImmunityBio position peaked at $77.9M in Q4 2015.
47 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2019.

Based on Wildcat Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.